TR score: A noninvasive model to predict histological stages in patients with primary biliary cholangitis

Front Immunol. 2023 Mar 16:14:1152294. doi: 10.3389/fimmu.2023.1152294. eCollection 2023.

Abstract

Introduction: The aim of this study was to develop a noninvasive prediction model for histological stages in PBC that is simple, easy to implement, and highly accurate.

Methods: A total of 114 patients with PBC were included in this study. Demographic, laboratory data and histological assessments were collected. The independent predictors of histological stages were selected to establish a noninvasive serological model. The scores of 22 noninvasive models were calculated and compared with the established model.

Results: This study included 99 females (86.8%) and 15 males (13.2%). The number of patients in Scheuer's stage 1, 2, 3 and 4 was 33 (29.0%), 34 (29.8%), 16 (14.0%), and 31 (27.2%), respectively. TBA and RDW are independent predictors of PBC histological stages. The above indexes were used to establish a noninvasive model-TR score. When predicting early histological change (S1) or liver fibrosis and cirrhosis (S3-S4), the AUROC of TR score were 0.887 (95% CI, 0.809-0.965) and 0.893 (95% CI, 0.816-0.969), higher than all of the other 22 models included in this study. When predicting cirrhosis (S4), its AUROC is still as high as 0.921 (95% CI, 0.837-1.000).

Conclusion: TR score is an easy, cheap and stable noninvasive model, without complex calculation formulas and tools, and shows good accuracy in diagnosing the histological stages of PBC.

Keywords: histological stage; noninvasive model; primary biliary cholangitis; red blood cell distribution width; total bile acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Fibrosis
  • Humans
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis, Biliary* / diagnosis
  • Liver Cirrhosis, Biliary* / pathology
  • Male
  • Severity of Illness Index

Grants and funding

This research was funded by the National Natural Science Foundation of China (No.82170535) and the Program of Jilin Financial Department (No. JLSCZD2019-027).